hypopharynx cancer: A primary or metastatic malignant neoplasm that affects the hypopharynx.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519972 |
1. Apply sex-specific ruleNone |
519972 |
2. Check conditionsNone |
519972 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
107 |
4. Check minimum number of eventsNone |
107 |
5. Include endpointsNone |
107 |
6. Filter based on genotype QC (FinnGen only) |
99 |
Control definitions (FinnGen only)
Controls for this endpoint are individuals that are not cases.
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF2
Similar endpoints
↥List of similar endpoints to
Benign neoplasm: Carotid body
based on the number of shared cases.
Similar with more cases:
- Benign neoplasm of other and unspecified endocrine glands
- Benign neoplasms
- Neoplasms
- Any operation in hilmo
- Any event in hilmo or specialist outpatient
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 527 | 324 | 199 |
| Only index persons | 492 | 306 | 186 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.01 | 0.01 | 0.01 |
| Only index persons | 0.01 | 0.01 | 0.01 |
| Median age at first event (years) | |||
| Whole population | 56.26 | 58.33 | 52.76 |
| Only index persons | 55.32 | 57.80 | 51.23 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 99 | 59 | 40 |
| Unadjusted period prevalence (%) | 0.02 | 0.02 | 0.02 |
| Median age at first event (years) | 56.20 | 55.18 | 57.69 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 107
- Matched controls
- 1070
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
D35.59
ICD-10 Finland
Other paragangliom
+∞
88.1
72
*
D35.50
ICD-10 Finland
Carotid body
+∞
52.5
46
*
BDA10
NOMESCO Finland
Operation on carotid body
+∞
18.2
17
*
WX408
NOMESCO Finland
General anesthesy, balanced
5.1
15.7
53
173
DCB00
NOMESCO Finland
Excision of lesion of middle ear
+∞
10.6
10
*
H02AB09
ATC
hydrocortisone; systemic
15.4
10.0
16
12
EP1CG
NOMESCO Finland
Extensive MRI examination of soft tissue of neck with high intesity magnet
+∞
9.5
9
*
Z31.5
ICD-10 Finland
Genetic counselling
8.5
9.3
20
28
D14.0
ICD-10 Finland
Benign neoplasm: Middle ear, nasal cavity and accessory sinuses
54.6
8.8
10
*
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
4.9
8.8
22
54
102
Kela drug reimbursment
Diabetes insipidus
97.4
8.5
9
*
E23.00
ICD-10 Finland
Panhypopituitarism
97.4
8.5
9
*
8680/3-C75.5
ICD-O-3
Paraganglioma, NOS, of aortic body and other paraganglia
+∞
8.4
8
*
E27.5
ICD-10 Finland
Adrenomedullary hyperfunction
+∞
8.4
8
*
AA4CG
NOMESCO Finland
Extensive MRI examination of sella turcica with high intensity magnet
36.4
8.2
10
*
TPH07
NOMESCO Finland
Cathetrisation of artery
4.8
7.9
20
49
D35.2
ICD-10 Finland
Benign neoplasm: Pituitary gland
27.3
7.7
10
*
D35.30
ICD-10 Finland
Craniopharyngoma
85.8
7.5
8
*
D35.6
ICD-10 Finland
Benign neoplasm: Aortic body and other paraganglia
+∞
7.4
7
*
D35.9
ICD-10 Finland
Benign neoplasm: Endocrine gland, unspecified
+∞
7.4
7
*
101
Kela drug reimbursment
Anterior pituitary hypofunction
24.3
6.8
9
*
9350/1-C75.2
ICD-O-3
Craniopharyngioma, NOS, of craniopharyngeal duct
74.1
6.5
7
*
JN5ER
NOMESCO Finland
PET-CT of receptors in whole body
74.1
6.5
7
*
EP1AE
NOMESCO Finland
Neck ultrasound examination
7.1
6.4
15
24
PA5DT
NOMESCO Finland
Embolisation of a tumor of carotis externa area
+∞
6.3
6
*
H01BA02
ATC
desmopressin; nasal, systemic, sublingual
13.6
6.2
10
8
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
42
13
52.54
68.11
4.4
1.2
0.17
—
nmol/l
—
14
0
41
12
54.16
35.12
4.4
1.1
2.79
4.42
nmol/l
0.51
41
12
72
423
3.15
7.28
6.2
8.2
1.21
1.22
mmol/l
0.79
56
372
66
410
2.59
5.36
2.6
2.8
—
—
—
0
0
10
13
8.35
4.97
1.2
1.1
203.40
289.46
pmol/l
—
10
13
7
5
14.83
4.64
2.6
1.0
58.14
49.80
nmol/l
—
7
5
22
88
2.89
4.21
4.5
13.6
1.81
1.24
mmol/l
0.31
17
71
21
85
2.83
3.92
4.3
3.3
—
—
—
0
0
6
6
10.49
3.54
2.2
1.3
9.17
12.67
ug/l
—
6
6
98
825
3.23
3.53
4.5
4.8
1.78
1.82
mu/l
0.12
91
752
9
18
5.35
3.45
1.0
1.3
—
—
—
0
0
6
7
8.99
3.30
1.5
1.1
—
—
—
0
0
6
9
6.98
2.90
1.3
1.1
—
—
—
0
0
29
159
2.13
2.80
3.4
3.2
706.53
101.25
ng/l
0.48
19
112
9
26
3.68
2.55
1.9
2.5
—
—
—
0
0
33
200
1.94
2.40
1.8
2.6
—
—
—
0
0
13
54
2.60
2.30
4.8
8.0
24.82
25.11
mmol/l
0.09
13
54
96
831
2.51
2.27
16.8
12.8
83.56
83.83
ml/min/173m2
0.04
85
673
5
9
5.76
2.24
1.0
1.3
—
—
—
0
0
24
133
2.04
2.23
2.5
1.7
—
—
—
0
0
52
376
1.75
2.10
2.8
2.5
73.84
77.05
nmol/l
0.32
46
330
62
477
1.71
1.96
5.8
7.2
19.29
10.38
umol/l
0.61
62
452
11
46
2.55
1.92
5.6
11.9
94.02
95.01
%
0.26
11
46
35
231
1.77
1.91
3.6
4.1
0.00
0.00
estimate
-0.00
14
80
52
390
1.65
1.75
8.8
12.0
1.19
1.25
inr
0.25
18
115
34
230
1.70
1.68
2.8
3.1
1264.15
1163.84
ng/l
0.05
29
194
39
280
1.62
1.52
2.4
2.7
50.41
53.34
u/l
0.29
39
264
45
346
1.52
1.27
4.0
3.8
—
—
—
0
0
7
30
2.42
1.14
1.9
2.2
—
—
—
0
0
7
32
2.27
1.10
2.0
2.4
—
—
—
0
0
15
91
1.75
1.07
2.3
1.5
—
—
—
0
0
5
22
2.33
1.04
1.0
1.4
—
—
—
0
0
5
22
2.33
1.04
1.0
1.4
—
—
—
0
0
8
142
0.53
1.02
1.5
1.4
—
—
—
0
0
54
445
1.43
1.02
3.9
3.7
0.00
0.00
estimate
-0.00
14
80
0
29
0.00
0.99
0.0
1.3
—
—
—
0
0
97
901
1.82
0.99
16.7
14.0
22.59
22.06
mg/l
0.06
82
703
25
178
1.53
0.98
3.2
4.3
17.84
21.67
%
0.69
14
79
53
440
1.41
0.94
5.3
5.2
0.00
0.00
estimate
-0.00
14
81
15
95
1.67
0.93
2.5
1.5
—
—
—
0
0
52
438
1.36
0.82
3.9
3.8
0.00
0.00
estimate
-0.00
14
87
6
33
1.87
0.80
1.8
1.4
0.20
0.23
g/l
—
6
33
6
34
1.81
0.77
2.0
3.4
9.17
281.93
u/ml
—
6
29
6
34
1.81
0.77
1.8
1.4
1.14
1.14
g/l
—
6
34
5
25
2.05
0.73
1.2
1.5
—
—
—
0
0
5
27
1.89
0.69
1.2
1.6
—
—
—
0
0
5
28
1.82
0.67
1.4
1.3
—
—
—
0
0
60
529
1.31
0.64
8.2
10.6
4.31
4.07
e9/l
0.32
53
461
10
63
1.65
0.64
2.2
2.1
5.03
5.55
ug/l
—
10
56
10
65
1.59
0.58
1.5
1.7
—
—
—
0
0
6
38
1.61
0.55
1.3
3.2
1.18
1.21
%
—
6
38
14
101
1.44
0.53
5.9
7.3
104.29
104.30
mmol/l
0.00
14
101
7
107
0.63
0.52
11.9
5.8
—
—
—
0
0
5
33
1.54
0.42
2.0
2.1
—
—
—
0
0
87
825
1.29
0.42
6.0
5.3
38.94
39.65
mmol/mol
0.34
81
776
17
133
1.33
0.42
1.9
3.0
0.79
0.71
ug/l
—
10
84
0
17
0.00
0.41
0.0
1.2
—
4.87
—
0
8
85
889
0.79
0.38
4.8
4.8
2.60
2.80
mmol/l
1.26
77
814
83
870
0.80
0.38
4.3
4.4
1.45
1.49
mmol/l
0.30
77
797
36
317
1.20
0.35
3.2
3.1
—
—
—
0
0
21
248
0.81
0.32
1.9
1.7
1.45
1.33
mmol/l
0.23
15
209
17
140
1.25
0.30
1.5
1.6
880.44
1145.28
nmol/l
—
9
106
80
834
0.84
0.28
3.9
4.0
1.50
1.30
mmol/l
0.99
75
758
64
601
1.16
0.27
3.2
3.1
—
—
—
0
0
36
325
1.16
0.26
3.9
3.5
17.14
31.11
ng/l
1.23
28
218
22
251
0.84
0.24
3.3
3.6
1.58
10.65
mg/mmol
3.06
11
158
12
146
0.80
0.24
2.3
2.8
5.60
3.16
e6/l
—
5
74
5
37
1.37
0.24
1.0
1.9
—
—
—
0
0
14
167
0.81
0.23
1.4
1.3
5.21
8.02
u/ml
—
7
70
7
95
0.72
0.23
1.9
1.7
—
—
—
0
0
5
42
1.20
0.22
3.0
4.6
23.52
24.65
mmol/l
—
5
42
0
10
0.00
0.21
0.0
1.0
—
—
—
0
0
0
10
0.00
0.21
0.0
1.3
—
—
—
0
0
0
10
0.00
0.21
0.0
3.1
—
—
—
0
0
0
12
0.00
0.21
0.0
1.7
—
—
—
0
0
0
12
0.00
0.21
0.0
1.3
—
—
—
0
0
0
12
0.00
0.21
0.0
1.3
—
—
—
0
0
9
110
0.80
0.21
1.7
2.3
—
—
—
0
0
0
13
0.00
0.21
0.0
1.9
—
—
—
0
0
0
13
0.00
0.21
0.0
1.3
—
—
—
0
0
0
13
0.00
0.21
0.0
1.3
—
—
—
0
0
0
13
0.00
0.21
0.0
1.3
—
—
—
0
0
87
843
1.17
0.20
5.0
4.3
5.88
5.89
mmol/l
0.03
80
770
0
14
0.00
0.20
0.0
1.3
—
1.20
—
0
5
0
14
0.00
0.20
0.0
1.1
—
—
—
0
0
6
51
1.19
0.20
1.3
1.7
—
—
—
0
0
85
875
0.86
0.19
4.4
4.4
4.57
4.72
mmol/l
0.68
78
807
17
193
0.86
0.17
1.7
1.9
0.60
1.29
mg/l
0.85
12
152
16
181
0.86
0.15
1.4
1.6
—
—
—
0
0
20
179
1.14
0.15
1.3
1.3
12.86
27.43
iu/ml
1.15
12
61
15
132
1.16
0.14
1.5
2.2
30.13
29.20
s
0.25
15
127
35
329
1.09
0.12
1.9
1.9
89.58
98.22
pmol/l
0.40
18
154
14
155
0.89
0.10
2.7
2.6
0.24
0.88
e6/l
—
8
83
5
47
1.07
0.09
1.4
1.2
—
—
—
0
0
9
104
0.85
0.06
1.7
2.1
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
12.62
—
0
6
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
2.6
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.8
—
—
—
0
0
0
8
0.00
-0.00
0.0
2.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
0.33
—
0
5
0
6
0.00
-0.00
0.0
1.3
—
1361.50
—
0
6
0
6
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.3
—
—
—
0
0
5
49
1.02
-0.00
1.0
1.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.8
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.8
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
4.4
—
247.78
—
0
5
0
8
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
6
0.00
-0.00
0.0
3.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
57.35
—
0
6
0
8
0.00
-0.00
0.0
2.1
—
—
—
0
0
0
6
0.00
-0.00
0.0
3.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
35.72
—
0
5
(40770918) von Willebrand factor (vWf).activity actual/normal in Platelet poor plasma by Immunoassay
0
5
0.00
-0.00
0.0
3.2
—
96.20
—
0
5
0
6
0.00
-0.00
0.0
1.8
—
—
—
0
0
0
6
0.00
-0.00
0.0
2.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
6
0.00
-0.00
0.0
2.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
-0.00
0.0
2.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
2.0
—
8.16
—
0
5
0
8
0.00
-0.00
0.0
2.0
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint CD2_BENIGN_CAROTIDBODY and mortality.
Females
No dataMales
No dataMortality risk
Mortality risk for people of age
years, who have CD2_BENIGN_CAROTIDBODY.| N-year risk | Females | Males |
|---|---|---|
| 1 | No data | No data |
| 5 | No data | No data |
| 10 | No data | No data |
| 15 | No data | No data |
| 20 | No data | No data |
Relationships between endpoints
↥Index endpoint: CD2_BENIGN_CAROTIDBODY – Benign neoplasm: Carotid body
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data